Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 194 Show results per page	View Search Criteria \| Help With Results


1.		Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Completed				40 and over				Pharmaceutical / Industry				102-12 NCT00090038


2.		MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Closed				18 to 120				Pharmaceutical / Industry				MO19872 NCT00430352

Last Modified: 8/26/2004 First Published: 7/26/2003


3.		Phase II/III Study of Rituximab and Interleukin-2 in Patients With Low-Grade or Follicular Non-Hodgkin's Lymphoma Refractory to Prior Single-Agent Rituximab

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				UCLA-0302013 CHIR-IL2NHL03-A01, NCT00066534


4.		Rituximab+Standard CHOP vs Rituximab+bi-Weekly CHOP for Untreated Stage III/IV Low-Grade B-Cell Lymphoma (JCOG0203)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				20 to 69				Other				JCOG0203 C000000033, NCT00147121

Last Modified: 12/6/2007 First Published: 8/1/1997


5.		Phase III Study of Early High-Dose Chemoradiotherapy and Autologous Peripheral Blood Stem Cell Transplantation Versus Conventional Dose Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Patients with Intermediate- or High-Grade Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				15 to 65				NCI				SWOG-S9704 CAN-NCIC-LY11, CALGB-59903, ECOG-S9704, S9704, NCT00004031, LY11

Last Modified: 8/2/2007 First Published: 1/1/1998


6.		Phase III Randomized Study of CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) With or Without Rituximab in Older Patients With Diffuse Mixed, Diffuse Large, or Immunoblastic Large Cell Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				60 and over				NCI				ECOG-E4494 E4494, CLB-9793, SWOG-E4494, NCT00003150

Last Modified: 8/15/2007 First Published: 3/1/1998


7.		Phase III Randomized Study of Standard Therapy Followed by Maintenance Therapy With Rituximab (IDEC-C2B8 Monoclonal Antibody) or Observation in Patients With Stage III or IV Low Grade Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				NCI				E-1496 CLB-59902, NCT00003204, E1496

Last Modified: 2/27/2007 First Published: 5/1/1998


8.		Phase III Randomized Study of Rituximab Consolidation Following Rituximab Induction in Patients With CD20 Positive Follicular or Mantle Cell Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over								SWS-SAKK-35/98 ICR-35/98, EU-98009, NCT00003280

Last Modified: 12/1/1999 First Published: 7/1/1998


9.		Phase III Randomized Study of IDEC-Y2B8 Radioimmunotherapy Versus Rituximab Immunotherapy for Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				Not specified				Pharmaceutical / Industry				IDEC-106-04 MAYO-977802

Last Modified: 5/25/2007 First Published: 12/1/1998


10.		Phase III Randomized Study of CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) With or Without Rituximab in Patients With Previously Untreated HIV-Associated Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				Over 18				NCI				AMC-010 CPMC-IRB-9691, CWRU-AMC-1400, UCLA-9810029, NCT00003595, AMC-010

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute